Mr. Kenneth Galbraith is Chief Executive Office of Prometic. He is also Managing Director of Five Corners Capital. He joined Ventures West as a General Partner in 2007 and led the firm’s biotech practice prior to founding Five Corners Capital in 2013 to continue managing the Ventures West investment portfolio. Mr. Galbraith is a well-known and active member of the North American life sciences community with over 30 years of experience acting as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors.
Previously, Mr. Galbraith served as the Chairman and Interim CEO of AnorMED, a biopharmaceutical company focused on new therapeutic products in hematology, HIV and oncology, until its sale to Genzyme Corp. in a cash transaction worth almost US$600 million. Starting in the biotech sector in 1987, Mr. Galbraith spent 13 years in senior management with QLT Inc., a global biopharmaceutical company specializing in developing treatments for eye diseases and oncology, retiring in 2000 from his position as Executive VP and CFO when QLT’s market capitalization exceeded US$5 billion. He has served on the board of directors of several public and private biotechnology companies, including Zymeworks, Angiotech Pharmaceuticals (ANPI), Aquinox (AQXP), Alder Pharmaceuticals (ALDR), Tekmira (TKMR) and Cardiome Pharma (CRME). He currently serves on the Board of Directors of Macrogenics (MGNX) and Profound Medical.
Mr. Galbraith earned a Bachelor of Commerce (Honours) degree from the University of British Columbia in 1985 and appointed a Fellow of the Chartered Accountants of BC in 2013.
Bruce is the Chief Operating Officer- International of Prometic Life Sciences (PLI), a global biopharmaceutical company. As COO- International, Bruce oversees the company’s commercial, strategy, marketing, manufacturing, supply chain and business development functions.
An accountant by training, he has spent over two decades working in the life sciences and pharmaceutical industry. He has more than twelve years’ experience with PLI and has held a number of senior global positions across the organisation.
Prior to being appointed COO in 2014, Bruce was the Group CFO, a role he had held since 2008. Bruce brings a proven track record of success in strategic acquisitions and in raising debt and equity finance. As the finance director for Ardana, a speciality pharmaceutical company, he was responsible for raising the venture capital for the company’s successful IPO.
As well as being a chartered accountant, Bruce also brought to the role many years of experience in general management and operations. Prior to joining Prometic, Bruce worked as a senior director for CV Therapeutics, a NASDAQ listed biopharmaceutical company, with a market capitalisation of over US$1 Billion.
Bruce is a graduate of Heriot-Watt University where he gained a BA in Accountancy and Computer Science. He is a member of the Institute of Chartered Accountants of Scotland and a Fellow of the Institute of Directors. He is also a Non-Executive Director and Chair of the Audit Committee of Imanova Limited.
Bruce splits his time between the group’s HQ in Montreal, Canada and its UK office in Cambridge.
Patrick is the Chief Operating Officer- North America of Prometic Life Sciences (PLI), a global biopharmaceutical company. Mr. Patrick Sartore joined Prometic in 2006 as Senior Legal Counsel – Intellectual Property, was nominated Corporate Secretary of the Corporation in 2007. Mr. Sartore held the position of General Counsel and Corporate Secretary from May 2013 to May 2015, at which date he was appointed Chief Legal Officer and Corporate Secretary.
Mr. Sartore was previously employed by Univalor Inc. as Legal Counsel and Leger Robic Richard, L.L.P., a firm specializing in Intellectual Property, Corporate and Commercial Law, as an associate attorney. Mr. Sartore has extensive experience in the areas of intellectual property, technology transfer, licensing and commercialization, private and public financing as well as general corporate and commercial law, namely in the biopharmaceutical field.
Mr. Sartore graduated from the University of Montreal with a Bachelor of Law (LLB) in 1999 and was called to the Bar of Québec in 2001. Mr. Sartore also holds a Bachelor of Science, with Distinction, from Concordia University.
Murielle Lortie is the Chief Financial Officer of Prometic Life Sciences (PLI). She has served as VP Finance of Prometic since September, 2018 and has held multiple senior positions within the pharmaceutical industry over the past 20 years.
Murielle brings a vast amount of experience in finance and corporate strategy. Prior to joining Prometic Murielle was employed as Vice President & Chief Financial Officer and Advisor to the CEO, Global Strategy, Mergers & Acquisitions at Pharmascience Inc. Previous to this, Murielle has held senior positions in finance at Bristol Myers Squibb including Vice-President of Finance for Bristol Myers Squibb Canada Co. and Global Director of Finance supporting BMS Headquarters.
Murielle also served as a Director on the Board of Bellus Health and Pharmascience Barbados Ltd & Pharmascience International Ltd.
Mrs. Lortie is a Chartered Professional Accountant & member of the Ordre des comptables professionnels agrées du Québec. She holds a Graduate Diploma in Accountancy from Concordia University and a Bachelor of Business Administration Bishop’s University.
Dr. John Moran MD, FRACP, FACP, has served as Chief Medical Officer of Prometic since March 1, 2014. From 2010 until joining the Corporation, Dr. Moran was Vice President, Clinical Affairs – Home modalities at DaVita Healthcare Partners Inc. where he had the overall responsibility for quality of care and related business issues for over 20,000 home dialysis patients in over 1,000 care centers.
Previously, Dr. Moran served for eight years as Senior Vice President, Clinical Affairs for Satellite Healthcare. Dr. Moran also served for, five years at Baxter Healthcare, as Global Medical Director for the Renal Division and for two years as Vice President for Clinical Development and Marketing.